{"transactions":[{"id":1937040,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":17517,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":17517,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":17517},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937039,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":157257,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":157257,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-12","underlying":"Common Stock","underlying_shares":157257},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937038,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17517,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":17517},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937037,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":157257,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-12","underlying":"Common Stock","underlying_shares":157257},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937036,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":209803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":730345,"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":2072900,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-03T19:38:18.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":53931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":520542,"source":{"system":"sec-edgar","filing":"0001567619-23-000067","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000156761923000067/doc1.xml","form_type":"4"}},{"id":2296511,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-15T19:58:23.000Z","date":"2022-04-14","kind":"grant","acquired":true,"shares":115931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 53,931 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates."}],"balance_after":466611,"source":{"system":"sec-edgar","filing":"0001567619-22-008614","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000156761922008614/doc1.xml","form_type":"4"}},{"id":2308794,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-04T16:16:03.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":306930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":350680,"source":{"system":"sec-edgar","filing":"0001140361-22-012918","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000114036122012918/form4.xml","form_type":"4"}},{"id":2544672,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2021-10-12T19:47:46.000Z","date":"2021-10-07","kind":"grant","acquired":true,"shares":436929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest 25% on the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":436929,"derivative":{"exercise_price":16,"expiration_date":"2031-10-07","underlying":"Common Stock","underlying_shares":436929},"source":{"system":"sec-edgar","filing":"0001140361-21-034424","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000114036121034424/form4.xml","form_type":"4"}},{"id":2544671,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-12T19:47:46.000Z","date":"2021-10-07","kind":"grant","acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock that vest 25% of the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":43750,"source":{"system":"sec-edgar","filing":"0001140361-21-034424","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000114036121034424/form4.xml","form_type":"4"}}]}